IP Verse

High Concentration Vegf Receptor Fusion Protein Containing Formulations

Patent No. EP4364724 (titled "High Concentration Vegf Receptor Fusion Protein Containing Formulations") was filed by Regeneron Pharmaceuticals on May 10, 2019. The application was issued on Nov 26, 2025.

Patent Summary

This invention provides a high-concentration VEGF receptor fusion protein, specifically aflibercept, for treating angiogenic eye disorders via intraocular injection. The treatment comprises administering a dose of approximately 8 mg of aflibercept in a volume of 100 $\mu$L or less (specifically 90, 80, 75, 70, 60, or 50 $\mu$L). Pharmaceutical formulations feature aflibercept concentrations from 80 mg/mL to 275 mg/mL and include a buffer, surfactant, and optionally a thermal stabilizer (e.g., sucrose, mannitol, sorbitol, trehalose) and/or a viscosity reducing agent. Some embodiments include taurine or propane sulfonic acid (25–100 mM) and maintain a pH of 5.0–6.8. The formulations are designed for stability, potency, and low viscosity, and may be provided in pre-filled sterile syringes compliant with USP<789> for small volume ophthalmic injections.

Patent Family

Patent Family

Patent Oppositions (13)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ALVOTECH HFAug 26, 2026EIP
HAMPTON KNOWLESAug 26, 2026D YOUNG
KAROAug 26, 2026-
KIVIALAug 26, 2026PETRAZ
BISCHOF & PARTNERAug 25, 2026BISCHOF
BOULT WADE TENNANTAug 25, 2026BOULT WADE TENNANT
KILBURN & STRODEAug 25, 2026LEONARD
NEUEFEINDAug 25, 2026MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH
QILU PHARMACEUTICALAug 25, 2026KARO
INTAS PHARMACEUTICALSAug 24, 2026TER MEER UND PARTNER
SANDOZAug 24, 2026MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH
ADVANZ PHARMA SERVICES UKAug 21, 2026POTTER CLARKSON
AMGENAug 21, 2026UEXKULL & STOLBERG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4364724

REGENERON PHARMACEUTICALS
Application Number
EP24156902A
Filing Date
May 10, 2019
Status
Granted And Under Opposition
Oct 24, 2025
Publication Date
Nov 26, 2025
External Links
Slate, Register , Google Patents